NVS

Today, 7:50 AMNovartis gets FDA priority review for del-zota in Duchenne muscular dystrophy

Peers: LLY AZN MRK ABBV JNJ PFE BMY GSK SNY AMGN

| Held by: DFIV DFAI DFIC PPH AVDE DIHP DFAX FENI FVD IDVO

Index	-
Market Cap	251.97B
Enterprise Value	293.70B
Income	12.76B
Sales	54.79B
Book/sh	22.69
Cash/sh	4.20
Dividend Est.	4.43 (3.22%)
Dividend TTM	4.74 (3.44%)
Dividend Ex-Date	Mar 11, 2026
Dividend Gr. 3/5Y	10.71% 8.17%
Payout	42.50%
Employees	75267
IPO	Nov 07, 1996

P/E	20.76
Forward P/E	14.05
PEG	2.18
P/S	4.60
P/B	6.07
P/C	32.77
P/FCF	15.02
EV/EBITDA	13.72
EV/Sales	5.36
Quick Ratio	0.67
Current Ratio	0.86
Debt/Eq	1.18
LT Debt/Eq	0.94
Option/Short	Yes / Yes

EPS (ttm)	6.63
EPS next Y	9.80
EPS next Q	2.21
EPS this Y	-2.20%
EPS next Y	11.56%
EPS next 5Y	6.44%
EPS past 3/5Y	31.40% 15.24%
Sales past 3/5Y	9.03% 2.29%
EPS Y/Y TTM	-4.08%
Sales Y/Y TTM	2.33%
EPS Q/Q	-18.54%
Sales Q/Q	0.97%
Earnings	Jul 21 BMO
EPS/Sales Surpr.	10.95% 2.43%

Insider Own	0.01%
Insider Trans	0.00%
Inst Own	7.49%
Inst Trans	-0.21%
ROA	11.27%
ROE	30.56%
ROIC	15.82%
Gross Margin	74.08%
Oper. Margin	29.58%
Profit Margin	23.29%
SMA20	-11.54%
SMA50	-11.35%
SMA200	-8.09%
Trades

Shs Outstand	1.83B
Shs Float	1.83B
Short Float	0.27%
Short Ratio	2.59
Short Interest	4.99M
52W High	170.46 -19.25%
52W Low	121.57 13.22%
Volatility	1.45% 1.44%
ATR (14)	4.78
RSI (14)	31.85
Beta	0.41
Rel Volume	5.61
Avg Volume	1.93M
Volume	6,362,188

Perf Week	-9.48%
Perf Month	-11.95%
Perf Quarter	-5.99%
Perf Half Y	-15.44%
Perf YTD	-0.16%
Perf Year	6.94%
Perf 3Y	47.92%
Perf 5Y	66.11%
Perf 10Y	102.37%
Recom	2.52
Target Price	156.32
Prev Close	159.99
Price	137.65
Change %	-13.96%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-26	Upgrade	Argus	Hold → Buy	$180
Jan-27-26	Initiated	Citigroup	Buy
Jan-06-26	Upgrade	Barclays	Underweight → Equal Weight
Dec-08-25	Upgrade	JP Morgan	Neutral → Overweight
Dec-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-25-25	Upgrade	BofA Securities	Neutral → Buy
Sep-12-25	Downgrade	Goldman	Neutral → Sell	$118
Aug-08-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$123
Feb-13-25	Downgrade	UBS	Buy → Neutral
Feb-12-25	Initiated	Morgan Stanley	Underweight
Feb-04-25	Upgrade	Deutsche Bank	Hold → Buy
Dec-04-24	Downgrade	HSBC Securities	Hold → Reduce
Sep-11-24	Downgrade	BofA Securities	Buy → Neutral	$135 → $130
Sep-05-24	Downgrade	Goldman	Buy → Neutral
Sep-03-24	Downgrade	Jefferies	Buy → Hold
Jul-19-24	Downgrade	Deutsche Bank	Buy → Hold
May-30-24	Initiated	Goldman	Buy	$120
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy

Show Previous Ratings

Today 12:59PM	Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails (GuruFocus.com) -13.96%
12:46PM	European shares muted as oil rally fuels caution; Novartis tumbles (Reuters)
11:49AM	Novartiss Pipeline Just Lost Two Big Bets (Moby)
11:04AM	Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial (Proactive)
10:33AM	Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday (Investopedia)
10:25AM	Loading…
10:25AM	Novartis and Boston Scientific Slide, Intel Price Hikes \| Stock Movers (Bloomberg)
09:57AM	Healthcare stocks tumble (MarketWatch)
09:10AM	Novartis Stock Falls 12% on Its Third Trial Setback In a Week (GuruFocus.com)
08:57AM	Novartis Is Having a Very Bad September-and More Pain Could Be on the Way (Barrons.com)
08:56AM	Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly (Quartz)
08:16AM	5 Things to Know Before the Stock Market Opens on Tuesday (Investopedia)
07:34AM	Novartis del-desiran drug trial fails, stock drops 9% (Quartz)
07:28AM	BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts (Investing.com)
07:26AM	Novartis twin drug setbacks pile pressure on pipeline and CEO (Reuters)
06:56AM	Beneath the surface, the next market leaders are getting ready to break out, says Morgan Stanley (MarketWatch)
06:54AM	Loading…
06:54AM	Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint (InvestorsHub)
06:52AM	Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade (InvestorsHub)
06:50AM	Novartis $12bn Avidity bet falters on late-stage del-desiran flop (Clinical Trials Arena)
06:26AM	Novartis DM1 Drug Misses Primary Endpoint in Phase III Trial (InvestorsHub)
05:39AM	Novartis India acquires Pfizer brands for $132m (Pharmaceutical Business Review)
04:15AM	Why the Dow is being dragged down by a Swiss company's bad news (MarketWatch)
Sep-07-26 05:46PM	Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar (GuruFocus.com)
01:50PM	Novartis Falls 1.9% as Pelacarsen Failure Erases CHF4.9 Billion (GuruFocus.com)
12:33PM	European shares subdued as surging crude sharpens focus on ECB rate path (Reuters)
10:44AM	Novartis Just Lost a Potential $6 Billion Drug Opportunity (GuruFocus.com)
06:35AM	Novartis Shares Fall After Pelacarsen Misses Primary Goal in Late-Stage Heart Trial (InvestorsHub)
06:00AM	Weight loss is just the beginning of GLP-1's: Novo Nordisk CEO (Yahoo Finance Video)
Sep-05-26 08:51AM	Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines (BioPharma Dive)
Sep-04-26 06:52PM	NVS, IONS, AMGN Stocks Drop After-Hours Whats Driving The Selloff? (Stocktwits) -13.96%
09:10AM	Novartis and Bristol Myers are halting cell therapy trials for autoimmune diseases after patient deaths (Quartz)
05:37AM	Loading…
Sep-03-26 05:37AM	Novartis signs drug delivery deal with Alteogen (Pharmaceutical Technology)
05:37AM	Novartis signs $3.2bn drug delivery deal with Alteogen (Pharmaceutical Technology)
05:37AM	Novartis signs deal with Alteogen for drug delivery (Pharmaceutical Business Review)
Sep-02-26 12:02PM	Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery (GuruFocus.com)
08:33AM	Novartis stock rises after MS drug remibrutinib trial results (Quartz)
08:33AM	Novartis stock surged after its oral multiple sclerosis pill passed two late-stage trials (Quartz)
08:32AM	Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
08:00AM	Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials (Proactive)
Sep-01-26 03:27PM	TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis (Stocktwits) +6.04%
01:24PM	Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials (GuruFocus.com)
10:36AM	Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping (Investopedia)
09:43AM	Novartis Halts Eight Trials After Three Patient Deaths (GuruFocus.com)
07:34AM	Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths (Barrons.com)
06:19AM	Premarket movers: GoPro soars 80% as Sono Group soars on Sports One deal (Investing.com)
Aug-31-26 01:38PM	Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns (BioPharma Dive)
Aug-25-26 01:05AM	IBRX Stock Extends 3-Day Slide Founder Teases New Trial In Unstoppable Cancer-Treatment Push (Stocktwits)
Aug-19-26 02:07PM	Palantir Stock Climbs as Enterprise AI Demand Keeps Growing (GuruFocus.com)
Aug-07-26 12:43PM	Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook (GuruFocus.com)
Aug-05-26 01:05AM	Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... (GuruFocus.com)
Aug-04-26 06:20AM	J&J pharma leader to retire; Krystal slumps on gene therapy miss (BioPharma Dive)
Aug-03-26 06:47PM	NH joins $469M multistate settlement with generic drug maker Sandoz over price-fixing claims (New Hampshire Union Leader, Manchester)
10:55AM	Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison (IPO-Edge.com)
09:08AM	Medicus Pharma CMO to lead Antev's Teverelix clinical programme (Proactive)
Jul-30-26 05:04PM	Alnylam Pharmaceuticals Inc (ALNY) (Q2 2026) Earnings Call Highlights: Amvuttra Surpasses $1 ... (GuruFocus.com)
05:12AM	How Telix landed a $2.1 billion radiopharma deal with Regeneron (Pharma Voice)
Jul-29-26 06:02AM	Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs (Barrons.com)
Jul-23-26 11:56AM	Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor (FinanceWire)
Jul-21-26 04:02PM	AI is helping speed up the timelines of drug discovery, Novartis CEO says (Yahoo Finance Video)
03:00PM	Novartis AG (NVS) Q2 2026 Earnings Call Highlights: Strong Growth in Key Brands Amidst ... (GuruFocus.com)
01:12PM	Novartis Profit Beats Estimates as Entresto Sales Plunge 50% (GuruFocus.com)
09:24AM	Novartis Q2 2026 earnings beat as cancer, MS drugs drive growth (Quartz)
09:22AM	U.S. stocks set for higher open as strong earnings boost market sentiment: Dow Jones, S&P, Nasdaq, Wall Street Futures (InvestorsHub)
08:15AM	Novartis Earnings Beat, Cash Flow Weakens (GuruFocus.com)
07:31AM	Novartis Q2 profits recover as revenue mantle passes to newer medicines (Pharmaceutical Technology)
06:53AM	Novartis returns to sales growth in Q2 as newer medicines offset generic pressure (NVS) (InvestorsHub)
02:58AM	Novartis says buoyed by new treatments in second quarter (AFP)
01:51AM	Novartis: Q2 Earnings Snapshot (Associated Press)
Jul-20-26 11:15AM	Novartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks? (FX Empire)
09:16AM	Earnings To Watch: Novartis AG (XSWX:NOVN) Reports Q2 2026 Result (GuruFocus.com)
06:05AM	Novartis pipeline faces critical test as upcoming trial results underpin growth outlook (InvestorsHub)
04:54AM	Bristol Myers to build powerful AI factory; Samsung Biologics bids for peptide maker (BioPharma Dive)
Jul-17-26 07:36AM	FDA grants traditional approval to Novartis' Fabhalta for IgAN (Pharmaceutical Business Review)
Jul-16-26 08:05AM	Why Abbott Earnings Are Sending the Stock Higher (Barrons.com)
Jul-14-26 06:14AM	Novartis and Chai Discovery collaborate on antibody identification (Pharmaceutical Business Review)
Jul-09-26 07:03AM	This Analyst Sees 34% Upside For SRPT Stock Here's Why They Expect A Sustained Rally Next (Stocktwits)
Jul-07-26 12:38PM	Novartis Buys Myricx Bio in $1.5 Billion Deal (GuruFocus.com)
Jul-06-26 11:30AM	Novartis is buying a U.K. cancer drug startup for up to $1.5 billion (Quartz)
11:29AM	Novartis acquires U.K. cancer biotech Myricx Bio for $1.5 billion (Quartz)
09:47AM	Novartis Buys Myricx Bio in Up to $1.5 Billion Cancer Drug Deal (GuruFocus.com)
07:05AM	Novartis to acquire Myricx Bio in up to $1.5bn deal (Pharmaceutical Business Review)
Jul-03-26 06:05AM	European Commission approves Novartis' Itvisma to treat SMA (Pharmaceutical Business Review)
Jun-25-26 03:53PM	Candel Therapeutics Designates Mark Sims as CCO (Exec Edge)
09:34AM	Novartis Eyes $5 Billion Pluvicto Opportunity (GuruFocus.com)
06:10AM	Antares gets $105M from Novartis for new cancer drugs (BioPharma Dive)
Jun-24-26 01:47PM	Novartis Targets Hard-to-Treat Cancers (GuruFocus.com)
10:12AM	Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal (Pharmaceutical Technology)
Jun-23-26 08:20AM	Should You Buy Or Sell AbbVie Stock At $230? (Trefis)
Jun-21-26 01:21AM	Swiss voters likely to reject stricter neutrality proposal, poll shows (Investing.com)
Jun-19-26 05:13AM	ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain (Pharmaceutical Technology)
Jun-17-26 12:39PM	Vedana debuts with $46m to progress migraine therapies (Pharmaceutical Technology)
Jun-11-26 07:40AM	Novartis $12bn bet on Avidity well placed after mid-stage FSHD win (Clinical Trials Arena)
06:18AM	Novartis RNA drug acquired in $12B Avidity deal notches a trial win (BioPharma Dive)
Jun-09-26 05:19PM	FDA Clears Imvivas Dual-Target CAR-T for Autoimmune Diseases (Exec Edge)
11:05AM	Applied Digital inks hyperscaler deal, Vail Resorts cuts guidance (Yahoo Finance Video)
07:56AM	GSK doubles down on oncology with $10.6bn Nuvalent takeover (Pharmaceutical Technology)
Jun-03-26 07:57AM	Legend surges on early data for in vivo lymphoma cell therapy (BioPharma Dive)
Jun-02-26 11:28AM	ASCO 2026: Mixed SCLC result for Legends LB2102, Novartis expedites manufacture (Pharmaceutical Technology)
May-21-26 06:42AM	Podcast: Supply chains, obesity drugs, and patents dominate Q1 earnings trends (Medical Device Network)
May-20-26 11:01AM	BioArctic AB (BRCTF) Q1 2026 Earnings Call Highlights: Strong Sales and Strategic Partnerships ... (GuruFocus.com)
May-12-26 07:42AM	Pharmas manufacturing reconfigurations provide CDMOs with expansion opportunities (Pharmaceutical Technology)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Chief Executive OfficerDr. Vasant Narasimhan M.D.

President of USMr. Victor Bulto

President of InternationalDr. Patrick Horber M.D.

Chief Financial OfficerMr. Mukul Mehta

President of OperationsDr. Steffen Lang Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Bulto Carulla Victor	Officer	Apr 30 '26	Proposed Sale	148.10	6,800	1,007,093	Apr 30 12:05 PM
Marshall Fiona	Officer	Feb 12 '26	Proposed Sale	161.35	30,743	4,960,277	Feb 12 02:43 PM
Bulto Carulla Victor	Officer	Feb 09 '26	Proposed Sale	156.21	7,500	1,171,576	Feb 09 11:49 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Novartis AG ADR

Upgrade your Finviz experience